Core B - The developmental component of the UCSD CFAR is designed to facilitate and encourage new investigators and new ideas in HIV/AIDS research. The intent is to optimize opportunities for productive research by providing immediate financial support in association with resource support provided by the Core facilities. Three categories of developmental grants will be supported, although the number and type of these categories are flexible: (1) foster junior investigators;(2) support newly-recruited faculty involved with HIV-related research;and (3) respond rapidly to evolving research opportunities. Requests for submission of developmental grants are advertised through the Administrative Core twice a year for funding in January and July. Faculty at all four CFAR member institutions are eligible to apply. The submissions are evaluated by an expert review committee and additional ad hoc reviewers who are experts in the pertinent fields as needed. Scientific merit is the primary criterion for making the awards;however, fostering the development of junior investigators is an important programmatic goal that is also considered in prioritization of awards. The maximum amount for the awards currently given is $50,000 for unfunded junior investigators and $30,000 for others. Grants to senior investigators must receive prior approval from the NIAID CFAR Program Office. As part of their award, investigators are required to provide documentation of publications and peer-reviewed funding that result from the developmental awards. They are also required to cite CFAR developmental funds in publications resulting from work supported by developmental grants. The Developmental Core also coordinates the NCI-funded pilot grants in HIV malignancies, in partnership with the UCSD Moores Cancer Center. The CFAR and Cancer Center issue joint requests for applications and conduct joint reviews. The Developmental Core coordinates the CFAR portion of this collaboration. The Developmental Core has an active and effective mentorship program. With the growth of the CFAR, anticipate a greater number of innovative and timely projects will be funded, attracting new members and affiliates who can advance HIV and AIDS research.

Public Health Relevance

The CFAR Developmental Core provides critical funding for developmental projects, particularly to junior investigators. The funding and mentorship offered through the Developmental Core generate innovative research and pilot data for investigators to publish and to use to generate larger grant applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI036214-19A1
Application #
8520774
Study Section
Special Emphasis Panel (ZAI1-UKS-A (J1))
Project Start
1994-04-01
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
19
Fiscal Year
2013
Total Cost
$573,744
Indirect Cost
$111,440
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Naticchia, Matthew R; Laubach, Logan K; Tota, Ember M et al. (2018) Embryonic Stem Cell Engineering with a Glycomimetic FGF2/BMP4 Co-Receptor Drives Mesodermal Differentiation in a Three-Dimensional Culture. ACS Chem Biol 13:2880-2887
Blumenthal, Jill; Jain, Sonia; Mulvihill, Evan et al. (2018) Perceived versus calculated HIV risk: Implications for Pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr :
Kardava, Lela; Sohn, Haewon; Youn, Christine et al. (2018) IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat Immunol 19:1001-1012
Wagner, Karla D; Syvertsen, Jennifer L; Verdugo, Silvia R et al. (2018) A mixed methods study of the social support networks of female sex workers and their primary noncommercial male partners in Tijuana, Mexico. J Mix Methods Res 12:437-457
Bastos, Francisco I; Bastos, Leonardo Soares; Coutinho, Carolina et al. (2018) HIV, HCV, HBV, and syphilis among transgender women from Brazil: Assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Medicine (Baltimore) 97:S16-S24
Cepeda, Javier A; Eritsyan, Ksenia; Vickerman, Peter et al. (2018) Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV 5:e578-e587
Namazi, Golnaz; Fajnzylber, Jesse M; Aga, Evgenia et al. (2018) The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis 218:1954-1963
Lada, Steven M; Huang, Karissa; VanBelzen, D Jake et al. (2018) Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol 56:
Huang, Mia L; Michalak, Austen L; Fisher, Christopher J et al. (2018) Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State. Stem Cells 36:45-54
Skaathun, Britt; Voisin, Dexter R; Cornwell, Benjamin et al. (2018) A Longitudinal Examination of Factors Associated with Network Bridging Among YMSM: Implications for HIV Prevention. AIDS Behav :

Showing the most recent 10 out of 921 publications